Merck paying $950 million to settle US Vioxx criminal, civil charges
This article was originally published in Scrip
Merck has agreed to plead guilty to violating the Food, Drug and Cosmetic Act (FDCA) and pay $950 million to settle US criminal charges and civil claims for off-label promotion of its cyclooxygenase-2-selective nonsteroidal anti-inflammatory drug Vioxx (rofecoxib), the US Department of Justice (DOJ) and the company said on 22 November.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.